The booster vaccination trial is still ongoing and further data will provide more information around safety and efficacy.
Japan’s Ministry of Health, Labour and Welfare (MHLW) has recently approved AstraZeneca's long-acting antibody combination “Evusheld” for the prevention ) and treatment of COVID-19.
Pfizer’s Paxlovid is approved by US FDA for COVID treatment
The approved product has an estimated market size of around US $62 million for the twelve months ending June 2022 according to IQVIA
Proportion of the eligible population yet to receive a COVID-19 vaccine is comparatively small
The Congress was held on June, 20-21, 2022 in Berlin, Germany
The proposed combination involves corporate restructuring of JVCO, including through acquisition by Haleon via demerger
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
Dr. Bernstein will tap into her decades of leadership and strategy experience as she transitions into this new role at APhA
The proposed demerger is the most significant corporate change for GSK in the last 20 years
Subscribe To Our Newsletter & Stay Updated
